New Post-Hoc Analysis Of Pooled Phase 3 Data Shows That INPEFA (Sotagliflozin) Reduced Risk Of Heart Failure Events In Patients With Preserved Ejection Fraction
New Post-Hoc Analysis Of Pooled Phase 3 Data Shows That INPEFA (Sotagliflozin) Reduced Risk Of Heart Failure Events In Patients With Preserved Ejection Fraction
对合并的3期数据的新事后分析表明，INPEFA（Sotagliflozin）在射血分数保持不变的情况下降低了患者发生心力衰竭的风险
New Post-Hoc Analysis Of Pooled Phase 3 Data Shows That INPEFA (Sotagliflozin) Reduced Risk Of Heart Failure Events In Patients With Preserved Ejection Fraction
对合并的3期数据的新事后分析表明，INPEFA（Sotagliflozin）在射血分数保持不变的情况下降低了患者发生心力衰竭的风险
译文内容由第三方软件翻译。
以上内容仅用作资讯或教育之目的，不构成与富途相关的任何投资建议。富途竭力但不能保证上述全部内容的真实性、准确性和原创性。